A combined test performed at the  th week of gestation enables us to classify the pregnancy as high risk (risk higher than :) or low risk (risk lower than :) for congenital foetal anomalies, with great accuracy of  -. According to the available data, the frequency of false positive results is estimated at around . e objective of the study was to examine possible correlation between the serum marker values and amniocentesis results in prenatal diagnostics of congenital foetal anomalies. e study included  pregnant women monitored by the Genetic Counselling Service of the Clinic of Gynaecology and Obstetrics of the Clinics Centre Kragujevac. e subjects were included in the study under condition that CRL (embryonic crown-rump length) was from  to  mm and that the gestational age was at -+ weeks. Free β HCG and PAPP-A were determined from venous blood using commercial DPS-USA tests. Tests were based on the analytic principle of the immuno-chemiluminescence technique and were performed by application of the automatic Immulite  analyzer by DPC-USA. e foetal nuchal translucency thickness (NT) and CRL were measured by Colour Doppler. e chromosome identifi cation was performed after a certain number of cell divisions by stopping the cell division in metaphase of mitosis when the chromosomes were the most distinguishable. e foetal karyotype was prepared using G bands. In the total sample of pregnant women (n=), there were six cases of pathological foetal karyotype. A statistical paradox in the frequency of congenital foetal anomalies in favour of younger population was noticed. A high coeffi cient of Spearman's rank correlation suggests great importance of the combined test in the detection of congenital foetal anomalies (p<,). A high consistency was also proved for components of biochemical screening and ultrasonographic markers. e combined test, as a method of prenatal screening in the fi rst trimester of pregnancy, if used at  -+ weeks' gestation and for CRL of - mm, has a great importance in the detection of congenital foetal anomalies.
Introduction
In our country, no offi cial guidelines for screening for Down syndrome exist. However, most perinatologists, after biochemical screening in the fi rst trimester of pregnancy, perform a combined screening in accordance with the recommendations of the Foetal Medicine Foundation -FMF, London. Performing a combined test in the th week of gestation which includes a combined assessment of the presence of chromosomopathy by nuchal thickness scan between  and + weeks' gestation, when the crown to rump length is between  - mm, and a biochemical test -detection of serum PAPP-A markers and free ß-HCG, the pregnancy can be classifi ed as high risk (risk higher than :) or low risk (risk lower than :) with a great accuracy of  -. The frequency of false positive results in the literature is estimated at around  () . erefore, in recent years, perinatologists worldwide have tried to minimize the number of recommended invasive procedures. Primarily, "additional" ultrasound markers were introduced: nuchal translucency measurement, nasal bone scan, frontal-maxillary personal angle, Ductus venosus Doppler fl ow during atrial contraction and tricuspid regurgitation. is approach has an accuracy of , with  of false positives () . According to the latest recommendations by Foetal Medicine Foundation, London from  (Theoretical Course for the Certifi cate of Competence in Ultrasound Examination at -+ Weeks), high risk pregnancies are those in which the risk for T assessed by combined test is higher than :; moderate risk pregnancies are those with the combined test results in the range from : to :, while low risk pregnancies are those with the risk less than :. In this way the primary choice of pregnant women for an invasive procedure based on the test results is further decreased () . In the last few years, the aim of numerous investigations was to develop non-invasive methods of prenatal diagnosis based on isolation and examination of foetal cells from maternal blood. ese studies are based on the presence of foetal free (extracellular) DNA in maternal plasma and quantification of male DNA concentrations in pregnancies with male foetuses using the real time PCR.
Objective
The objective of the paper was to determine the correlation between the serum markers values and amniocentesis results in the prenatal diagnosis of congenital foetal anomalies.
Materials and Methods
is intervention observational study was carried out at the Clinic of Gynaecology and Obstetrics of the CC Kragujevac in the period from -. In the course of the study, the clinical-experimental method was used. Each patient was given a full explanation of the plan and the objective of the study and all the subjects gave their informed consent to participate. e Ethical Committee of the CC Kragujevac approved the study. It included  pregnant women monitored by the Genetic Counselling Service Committee of the Clinic of Gynaecology and Obstetrics of the CC Kragujevac. e study inclusion criteria involved: . The CRL (crown-rump length) between  and  mm. . e gestational age of -+ weeks.
Out of the total number of subjects,  underwent a complete laboratory examination with ultrasonographic scan at -+ weeks' gestation. e amniocentesis for determination of the fetal karyotype was performed in the whole sample of  pregnant women.
The obtained test results and serum and ultrasonographic marker values were compared with the early amniocentesis findings. This gave us an opportunity to establish their sensitivity, specifi city and predictive values in the detection of congenital foetal anomalies. e following parameters were analyzed: -PAPP-A (multiple of the median -MoM) -Free β HCG (multiple of the median -MoM)
Free β HCG and PAPP-A were measured from venous blood using commercial DPS-USA tests. The tests were based on the analytic principle of the immuno-chemiluminescence technique and were performed by application of the automatic Immulite  analyzer by DPC-USA The foetal nuchal translucency thickness (NT) and CRL were measured by Colour Doppler. For measurements of the foetal nuchal translucency thickness NT we used a high-resolution ultrasound device with a cine loop which allowed replay and a calliper which provided measurements in decimal form. Only the head and the upper chest were scanned. Since the magnification was maximal, the minimal movement of the calliper changed the measurement only by , mm. e nuchal translucency was measured on the foetus in the neutral position. e maximum thickness of subcutaneous translucency between skin and soft tissue was measured above the cervical spine. e CRL (crown-rump length) was measured by Colour Doppler. All ultrasound scans were performed using "Aloka prosound " at the Clinic of Gynaecology and Obstetrics of the Clinical Centre Kragujevac.
Cytological methods for chromosome identifi cation
After a certain number of cell divisions, plant alkaloid colchicine that prevents the formation of the mitotic spindle was added to the culture medium. The cells were arrested in the metaphase of mitosis when the chromosomes were the most distinguishable. After additional processing, the chromosomes were stained with Giemsa solution. Each chromosome presents specific and always the same pattern of bands (Gbands -stained with Giemsa). Then, the chromosomes were photographed, cut out and arranged in pairs by size, and the foetal karyotype was established. All the obtained data were stored in a unique database with an obligatory logic control. e statistic analysis included: -calculation of the mean value, SD, the value range for each numerical parameter, and analysis of the obtained values in relation to the subgroups, -Spearman's coeffi cient was used for assessment of correlation. The statistic data processing was performed on a PC using a statistical program SPSS for Windows and the obtained results were presented in tabular form with commentary.
Results
In the examined population of pregnant women, (n=),  or , of them had pathological amniocentesis findings. The average age of the examined pregnant women with physiological amniocentesis fi ndings was ,±,. e median value of fbHCG was ,±, mlU/ml, and the median value of PAPPA was ,±, mlU/ml. e corrected MoM for fbHCG was ,±,, and for PAPPA it was ,±,. The foetal CRL was ,±,mm, and the nuchal translucency (NT) was ,±,mm. e average gestation age with normal foetal karyotype was ,±, days.
The average age of the examined pregnant women with positive amniocentesis results was ,±,. In the same group, the median value of fbHCG was ,±,, and median value of PAPPA was ,±, ml/Uml. e corrected MoM for fbHCG was ,±,, and for PAPA the corrected MoM was ,±,. e average crown-rump length was ,±,, and the nuchal translucency thickness was ,±,mm. The average gestational age was ,±, days. Discussion e foetal nuchal translucency between -+ weeks of gestation combined with the mother's age represents an effective screening method for trisomy , which detects  of trisomic pregnancies with the rate of invasive interventions of . When free β-human chorionic gonadotropin and PAPP-A (pregnancy associated plasma protein A) in maternal blood between  and -+ weeks of gestation are taken into consideration, the detection rate of chromosomopathies rises to - (). Barclay () measured NT in a sample of  pregnant women and discovered  congenital foetal anomalies. There were  cases of trisomy , . of which had NT above  th percentile between - weeks of gestation. In the same study, this percentage decreases to   in the period between - weeks of gestation () . In , Manni () studied  foetuses of gestational age between - weeks. He measured NT in pregnant women whose average age was . In  (,) of the foetuses, NT was above  th percentile,  (,) of which had a normal karyotype. Out of  diagnosed chromosomopathies,  were trisomy  () .
e diameter of foetal nuchal translucency of  mm is associated with a threefold increase in the risk of trisomy , while the diameters of  mm,  mm and  mm are associated with -fold, -fold, and -fold increases. e nuchal translucency of  mm as a separate marker detects Down syndrome in   of the cases. PAPP-A is a protein that is synthesized in intervillous placental cytotrophoblast. It enables binding of the insulin-like growth factor (IGF) to proteins  and , thus enabling the interaction with cell receptors. The decreased PAPP-A activity causes stagnation in growth, preeclampsia, preterm births and pregnancy loss in his study, Spencer () stated that in the sample of   one foetus pregnancies in the fi rst trimester there was MoM PAPP-A lower than , or below  th which resulted in foetal loss before  weeks of gestation. Zournatzi () stated that the MoM value above , for fbHCG in the fi rst trimester, together with the MoM for PAPP-A below , detected trisomy  in  of the cases. e same author claimed that fbHCG combined with the pregnant woman's age at the same gestational age had a detection rate of up to  for trisomy  () . e combination of both bi˝ochemical parameters with the pregnant woman's age had a detection rate of . According to the published studies the level of free β-HCG in maternal blood normally decreases during gestation () . In pregnancies aff ected by trisomy , free β-HCG is increased.
e maternal blood levels of PAPP-A normally increase with gestation, while with pregnancies aff ected by trisomy  it decreases (). For a certain gestational age, the levels of β-HCG and PAPP-A present a probability factor that is multiplied with the initial risk in order to calculate the new risk () . e higher the level of β-HCG and the lower the level of PAPP-A, the higher the risk for trisomy  is. In pregnancies with trisomy , at  week of gestation, the free β-HCG concentration in maternal serum is higher than in pregnancies with foetuses without chromosomal abnormalities (around  MoM), while the PAPP-A concentration is lower (around , MoM). e diff erence in serum free β-HCG between normal pregnancies and those aff ected with trisomy  
Conclusion
We can conclude that the results of this study are in accordance with those found in the literature. e combined screening test, if used methodologically correctly, has a high predictive value for detection of congenital foetal anomalies, as indicated by the positive correlation coeffi cient. Statistical paradox seen in higher frequency of foetal anomalies in the population of pregnant women of younger age can be explained by the fact that prenatal diagnostic methods are more rarely used in this population. We must take into serious consideration the age cut-off as a rigid legal framework in implementation of measures in pregnant women's healthcare. We witness the time when a considerable number of pregnant women does not undergo invasive prenatal diagnosis thanks to screening tests. With the right choice and interpretation of available screening tests, we can prevent loss of recourses and waste of valuable time in making a diagnosis.
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